Eli Lilly shares were upgraded to Outperform at Leerink Partners, which cited “multiple waves of obesity treatment adoption drivers” and raised its price target to $1,104 from $886.

Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to ...

Following a slight dip in the last session, Eli Lilly (LLY) shares gained ~5% on Monday as Leerink Partners upgraded the pharma giant, arguing that its recent pricing deal with the Trump ...

In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...

Fintel reports that on November 10, 2025, Leerink Partners upgraded their outlook for Eli Lilly and (NYSE:LLY) from Market ...

The number of biopharma M&A deals announced so far this year is higher than the yearly average for the last 15 years, while deal value has already eclipsed last year’s total. | The number of biopharma ...

Cogent Biosciences expects to file a new drug application for bezuclastinib in gastrointestinal stromal tumors early next ...

Immunic, Inc. (NASDAQ:IMUX – Free Report) – Equities researchers at Leerink Partnrs dropped their Q1 2025 earnings estimates for Immunic in a research note issued on Tuesday, April 1st. Leerink ...

The gross proceeds to Evommune from the initial public offering before deducting underwriting discounts and commissions and offering expenses were $172.5 million. The shares began trading on the New ...

As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a ...

) or the potential repurchase of L'Oreal's 9% stake. Leerink Swann commented that they continue to see long-term opportunity for products including alirocumab and dupilumab, but "we are skeptical that ...

Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to buy. On October 21, Exelixis, Inc. (NASDAQ:EXEL) ...